Piccirillo, F.; Lanciotti, M.; Nusca, A.; Frau, L.; Spanò, A.; Liporace, P.; Ussia, G.P.; Grigioni, F.
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes. Int. J. Mol. Sci. 2025, 26, 2103.
https://doi.org/10.3390/ijms26052103
AMA Style
Piccirillo F, Lanciotti M, Nusca A, Frau L, Spanò A, Liporace P, Ussia GP, Grigioni F.
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes. International Journal of Molecular Sciences. 2025; 26(5):2103.
https://doi.org/10.3390/ijms26052103
Chicago/Turabian Style
Piccirillo, Francesco, Matteo Lanciotti, Annunziata Nusca, Lorenzo Frau, Agostino Spanò, Paola Liporace, Gian Paolo Ussia, and Francesco Grigioni.
2025. "Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes" International Journal of Molecular Sciences 26, no. 5: 2103.
https://doi.org/10.3390/ijms26052103
APA Style
Piccirillo, F., Lanciotti, M., Nusca, A., Frau, L., Spanò, A., Liporace, P., Ussia, G. P., & Grigioni, F.
(2025). Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes. International Journal of Molecular Sciences, 26(5), 2103.
https://doi.org/10.3390/ijms26052103
